FTC settles Amgen/Horizon challenge

Anna Langlois

05 September 2023

Shutterstock/Sundry Photography

Amgen and Horizon Therapeutics can proceed with their $27.8 billion merger after entering a settlement with the Federal Trade Commission that prevents the new company from bundling Horizon’s rare disease treatments.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Anna Langlois

View full biography

Author | News reporter, GCR USA

[email protected]

Tipline

Duking it out: The Tipline for 8 December 2023
Duke University might have thought its legal woes ended after settling with alumni claiming it was part of a financial aid cartel, but the battle is not over yet. The university has moved to the other side of the “v” and sued two of its insurance providers for refusing to cover the antitrust settlement. Also in Tipline, a former executive that worked in preventing soil erosion admits he rigged bids and the US Department …
Amateurism hour: The Tipline for 7 December 2023
In low Spirits: The Tipline for 6 December 2023

FTC settles Amgen/Horizon challenge

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Anna Langlois